scholarly article | Q13442814 |
P2093 | author name string | David A Price | |
Alan Frazer | |||
James L Roberts | |||
Andrea Giuffrida | |||
Lynette C Daws | |||
William A Owens | |||
Georgianna G Gould | |||
P2860 | cites work | Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry. | Q46567318 |
Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse | Q46744003 | ||
Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro | Q48127886 | ||
Cannabinoid modulation of electrically evoked pH and oxygen transients in the nucleus accumbens of awake rats | Q48547114 | ||
Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. | Q51976878 | ||
Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. | Q52030475 | ||
A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. | Q52186778 | ||
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter | Q24310836 | ||
Marijuana and cannabinoid regulation of brain reward circuits | Q24671514 | ||
Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons | Q28272251 | ||
In silico patent searching reveals a new cannabinoid receptor | Q28284495 | ||
Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata | Q28377147 | ||
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain | Q31570267 | ||
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra | Q34421920 | ||
Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats | Q35041427 | ||
Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor | Q35048967 | ||
Rapid regulation of the dopamine transporter: role in stimulant addiction? | Q35908701 | ||
[3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition | Q38312510 | ||
Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter | Q40623607 | ||
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. | Q42450193 | ||
Nigrostriatal dopamine release modulated by mesopontine muscarinic receptors | Q42464758 | ||
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
Effects of recording media composition on the responses of Nafion-coated carbon fiber microelectrodes measured using high-speed chronoamperometry. | Q43698340 | ||
Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse | Q44084440 | ||
Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism | Q44346123 | ||
Individual differences in cocaine-induced locomotor sensitization in low and high cocaine locomotor-responding rats are associated with differential inhibition of dopamine clearance in nucleus accumbens | Q44370408 | ||
Chloral hydrate and ethanol, but not urethane, alter the clearance of exogenous dopamine recorded by chronoamperometry in striatum of unrestrained rats | Q44443006 | ||
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. | Q44885114 | ||
Role of the dopamine transporter in the differential cocaine-induced locomotor activation of inbred long-sleep and short-sleep mice | Q44938350 | ||
Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex--involvement of Na(+)/K(+)-ATPase | Q44946148 | ||
Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 | ||
Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry | Q46373381 | ||
Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | dopamine | Q170304 |
cannabinoids | Q422936 | ||
striatum | Q1319792 | ||
P1104 | number of pages | 8 | |
P304 | page(s) | 389-396 | |
P577 | publication date | 2007-01-23 | |
P1433 | published in | Journal of Neurochemistry | Q6295643 |
P1476 | title | CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum | |
P478 | volume | 101 |
Q42087548 | A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease |
Q37200559 | Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder |
Q37752096 | Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas |
Q34899462 | Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. |
Q38522769 | Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia |
Q36157657 | Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe? |
Q38207680 | Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions |
Q37039010 | Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol |
Q33996977 | Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels |
Q34543977 | Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration |
Q37132571 | Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 |
Q36074595 | New insights on endocannabinoid transmission in psychomotor disorders |
Q34302209 | Permanent suppression of cortical oscillations in mice after adolescent exposure to cannabinoids: receptor mechanisms |
Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
Q38616780 | Psychostimulant Effect of the Synthetic Cannabinoid JWH-018 and AKB48: Behavioral, Neurochemical, and Dopamine Transporter Scan Imaging Studies in Mice. |
Q34540543 | Regulation of monoamine transporters: Role of transporter phosphorylation |
Q35848200 | Rescue of dopamine transporter function in hypoinsulinemic rats by a D2 receptor-ERK-dependent mechanism |
Q34181090 | The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. |
Q90623137 | The role of CA1 CB1 receptors on lithium-induced spatial memory impairment in rats |
Q37371387 | WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. |
Search more.